Daniel Schreeder

Hematology | Oncology
3601 Cci Dr Nw
Huntsville, AL 35805

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3 publications

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

Journal: JCI insight
Published: February 05, 2018

Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.

Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.

Journal: Cell
Published: January 04, 2018

FCRL3 promotes TLR9-induced B-cell activation and suppresses plasma cell differentiation.

FCRL3 promotes TLR9-induced B-cell activation and suppresses plasma cell differentiation.

Journal: European journal of immunology
Published: October 12, 2012
Showing 1-3 of 3

Last Updated: 09/26/2026